在目标上,双氨基酶抑制提供跨物种的抗疟疾活性
Rebecca C S Edgar1,2, Tess R Malcolm3, Ghizal Siddiqui4
1School of Medicine, Deakin University, Geelong, Australia.
mBio
|May 8, 2024
概括
一种新的抗疟疾化合物MMV1557817有效地抑制了疟疾寄生虫Plasmodium falciparum和Plasmodium vivax. 这种新型候选药物显示出对抗耐药菌株和多个寄生虫阶段的承诺,提供了一种潜在的新型抗疟疾疗法.
科学领域:
- 药用化学 医学化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 疟疾仍然是一个重大的全球健康负担,每年造成数十万人的死亡.
- 对基于美素的疗法的新兴耐药性需要开发具有新作用机制的新型抗疟疾药物.
- 目前的治疗方法面临药物耐药性的挑战,突显了迫切需要替代治疗策略.
研究的目的:
- 识别和描述针对关键寄生虫酶的新型抗疟疾化合物.
- 评估MMV1557817对各种疟疾寄生虫阶段和耐药菌株的疗效.
- 探索双M1和M17氨基酶抑制作为广泛的抗疟疾策略的潜力.
主要方法:
- 对化学库进行选,以确定Plasmodium falciparum和Plasmodium vivax aminopeptidases的抑制剂.
- 在体外测试以确定MMV1557817对无性和性寄生虫阶段的抑制活性.
- 在小鼠疟疾模型中评估MMV1557817活动,以及对抗药物耐药的寄生虫面板的评估.
- 产生和描述耐MMV1557817的寄生虫菌株.
主要成果:
- MMV1557817证明了选择性,纳米分子抑制Plasmodium falciparum和Plasmodium vivaxM1和M17氨基酶的发生.
- 该化合物有效地抑制了无性寄生虫的末期血红蛋白消化,并杀死了性阶段的P. falciparum.
- MMV1557817对小鼠疟疾表现出活性,与现有的抗疟疾药物没有交叉耐药性.
- 耐药的寄生虫菌株表现出较慢的生长和对素的敏感性增加,这表明一种自我限制的耐药机制.
结论:
- MMV1557817是开发新抗疟疾药物的有希望的化合物.
- 双抑制M1和M17氨基酶是针对多种疟疾的可行策略.
- MMV1557817的新奇机制和自我限制的耐药性概况为新一类抗疟疾疗法提供了希望.
关键词:
原菌 (Plasmodium falciparum) 是一种有毒的病毒.这是一种活性菌 (Plasmodium vivax).氨基胺酶的使用方法药物耐药性 耐药性 药物耐药性疟疾 疟疾 是一种疾病.更多相关视频
12:02An Efficient Method for the Synthesis of Peptoids with Mixed Lysine-type/Arginine-type Monomers and Evaluation of Their Anti-leishmanial Activity
Published on: November 2, 2016
12.1K
09:13Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
1.4K
相关概念视频
01:26Targets for Drug Action: Overview
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...